Less than one in 10 people who could benefit from obesity jabs such as Wegovy are able to get them, caution the WHO as it releases its initial guidance on the drugs.
Given in excess of 1,000,000,000 people worldwide now classified as obese, it is advocating for increased and just availability to these injectable treatments.
According to forecasts, over two billion are projected to be living with obesity by 2030 if no action is taken.
"The latest guidance recognises that excess weight is a long-term condition that can be managed with holistic and lifelong support," remarked its chief Tedros Adhanom Ghebreyesus.
Substantial prices, limited production capacity, and distribution challenges are major barriers to broad access to the jabs that can aid individuals in losing considerable weight, says the organization.
Even under the present most favorable scenario, the manufacturing of these medications would only suffice for around 100 million people – under 10% of the global need, as stated by the WHO.
The advice encourages countries and companies to expand access, through strategies such as licensing agreements.
The intellectual property rights on semaglutide – the primary ingredient of a leading brand – is set to lapse in several nations in 2026.
GLP-1 drugs mimick a natural hormone to slow digestion, curb appetite and increase the sense of being full so individuals eat less.
Individuals commonly begin shedding pounds after several weeks of starting on the weekly injections.
Studies suggests patients may put most of the weight back on after a year of halting the drug, when their usual food cravings resume.
Being above a healthy weight increases your likelihood for contracting diseases, like diabetes, heart disease, stroke, and some malignancies.
Excess weight impacts individuals in countries worldwide and was linked to 3.7 million fatalities worldwide in 2024, according to the health agency.